Engrail Therapeutics is a clinical-stage pharmaceutical company founded in 2019 with the aspiration of becoming a leader in neuroscience.  The company is committed to rapidly advancing its innovative, precision-targeted therapeutics for the treatment of diseases including anxiety disorders, depression, posttraumatic stress disorder, and rare neurodegenerative diseases.